Ai-Ping Xing

Ai-Ping Xing


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 December 2022 in Molecules
Verified
Journal Article
Open access
PDF file
HLHairong Lan
Hairong Lan
JSJunying SONG
Junying SONG
JYJuan Yuan
Juan Yuan
AXAi-Ping Xing
Ai-Ping Xing
DZDai Zeng
Dai Zeng
SFshuying FENG
shuying FENG
In the present paper, on the basis of molecular hybridization, a series of 4,6-dihydrazone pyrimidine derivatives containing the pyridine moiety were synthesized, structurally characterized, and evaluated in vitro for their antitumor activity. According to the results, all the tested compounds demonstrated broad-spectrum antitumor activity against selected tumor cell lines (MCF-7, BGC-823, A549, and BEL-7402) and no obvious toxicity toward normal cells HL-7702. In particular, compounds 10a and 10f were found to be the most promising antitumor agents among the tested compounds against BGC-823 cells (IC50 = 9.00 μM and 7.89 μM) and BEL-7402 cells (IC50 = 6.70 μM and 7.66 μM), respectively. Compounds 10a and 10f exhibited higher potency against BGC-823 and BEL-7402 than the positive control 5-FU (IC50 = 15.18 μM and 15.81 μM). Further mechanism investigations demonstrated that compounds 10a and 10f could significantly increase the level of cellular ROS and induce early apoptosis of BGC-823 cells in a dose-dependent manner. Moreover, the DNA binding results from UV/Vis, CD spectroscopy, and molecular docking studies indicated that 10a and 10f bind with DNA via groove binding and partial intercalation. These results demonstrated that 10a and 10f may serve as novel lead compounds for the discovery of more dihydrazone pyrimidine derivatives with improved antitumor potency and selectivity.

6 May 2024 in Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy
Verified
Journal Article
Closed access
YYYao-Yao Yuan
Yao-Yao Yuan
YHYa-Ting Hao
Ya-Ting Hao
DZDai Zeng
Dai Zeng
PPPan Pan
Pan Pan
JLJia-Xing Lu
Jia-Xing Lu
JYJuan Yuan
Juan Yuan

2 May 2025 in Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy
Verified
Journal Article
Closed access
BZBin Zhang
Bin Zhang
DZDai Zeng
Dai Zeng
YZYu-Xin Zhang
Yu-Xin Zhang
PPPan Pan
Pan Pan
JWJing Wang
Jing Wang
JYJuan Yuan
Juan Yuan

15 September 2023 in Zeitschrift für Kristallographie - New Crystal Structures
Verified
Journal Article
Open access
PDF file
DZDai Zeng
Dai Zeng
KTKai Tan
Kai Tan
ZFZiyan Fang
Ziyan Fang
AXAi-Ping Xing
Ai-Ping Xing
C24H19N3O, monoclinic, P21/c (no. 14), a = 10.4783(5) Å, b = 11.7171(5) Å, c = 14.9194(6) Å, β = 93.991(2)°, Z = 4, V = 1827.29(14) Å3, Rgt(F) = 0.0521, wR ref (F2) = 0.1508, T = 150(2) K.

27 May 2019 in Zeitschrift für Kristallographie - New Crystal Structures
Verified
Journal Article
Open access
PDF file
AXAi-Ping Xing
Ai-Ping Xing
DZDai Zeng
Dai Zeng
SZShu-Ling Zhang
Shu-Ling Zhang
JWJun-Jun Wei
Jun-Jun Wei
DGDa-Feng Guo
Da-Feng Guo
C22H27N3O, monoclinic, P21/c (no. 14), a = 18.4984(4) Å, b = 11.4221(3) Å, c = 9.79600(19) Å, β = 90.9652(19)°, V = 2069.51(8) Å3, Z = 4, R gt(F) = 0.0605, wR ref(F 2) = 0.1773, T = 293(2) K.

28 March 2019 in Zeitschrift für Kristallographie - New Crystal Structures
Verified
Journal Article
Open access
PDF file
AXAi-Ping Xing
Ai-Ping Xing
DZDai Zeng
Dai Zeng
C33H34N5O3Br, triclinic, P1̄ (no. 2), a = 9.1179(2) Å, b = 9.3291(3) Å, c = 18.4706(6) Å, α = 91.187(3)°, β = 95.764(2)°, γ = 102.256(2)°, Z = 2, V = 1526.15(8) Å3, R gt(F) = 0.0357, wR ref(F 2) = 0.0954, T = 105.7(5) K.